C4 Therapeutics Revenue and Competitors

Boston, MA USA

Location

$273.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • C4 Therapeutics's estimated annual revenue is currently $34M per year.(i)
  • C4 Therapeutics's estimated revenue per employee is $219,161
  • C4 Therapeutics's total funding is $273.8M.
  • C4 Therapeutics's current valuation is $1.3B. (January 2022)

Employee Data

  • C4 Therapeutics has 155 Employees.(i)
  • C4 Therapeutics grew their employee count by 29% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

C4 Therapeutics is pioneering a new class of drugs. C4's technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$273.8M

Total Funding

155

Number of Employees

$34M

Revenue (est)

29%

Employee Growth %

$1.3B

Valuation

N/A

Accelerator

C4 Therapeutics News

2022-04-19 - C4 Therapeutics (CCCC) – Research Analysts' Weekly ...

C4 Therapeutics (CCCC) – Research Analysts' Weekly Ratings Changes · 4/18/2022 – C4 Therapeutics had its price target lowered by analysts at UBS...

2022-04-17 - Contrasting PharmaCyte Biotech (OTCMKTS:PMCBD) & C4 ...

Get C4 Therapeutics alerts: 70.1% of C4 Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PharmaCyte Biotech...

2022-04-06 - Why C4 Therapeutics Stock Is Plunging Today - Benzinga

C4 is a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of...

2020-06-16 - C4 Therapeutics Raises $170M in Funding

C4 Therapeutics, Inc., a Watertown, Mass.-based biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, closed a $170m financing. This included $150m in Series B equity co-led by existing investor Cobro Ventures and ...

2016-01-07 - C4 Therapeutics Closes $73M Series A Financing

C4 Therapeutics, a Cambridge, MA-based developer of novel treatments in the field of targeted protein degradation, closed a $73m Series A round of financing. The round was led by Cobro Ventures with participation from Cormorant Asset Management, The Kraft Group, EG Capital Group, Roche, Novarti ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$17.3M1571%N/A
#2
$31.1M15715%N/A
#3
$25.1M16221%N/A
#4
$18.3M16610%N/A
#5
$52.6M1779%N/A